Akers Biosciences, Inc. AKER Cash Flow

Akers biosciences, inc. (AKER)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Cash flows from operating activities:
Net Loss
-6,509	-3,888	-6,386	-8,633	-9,906	-10,849	-11,032	-9,126	-7,877	-7,366	-4,440	-2,952	-3,143	-3,303	0	0	0	-	-	-	-	-	-	-	-2,182	-1,526	0	0	0
Net loss for the period
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on sale of securities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued (income)/loss on marketable securities
3	-3	-5	-8	-5	11	11	16	15	1	-0	-4	-4	-14	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
74	74	115	156	193	234	240	241	245	249	247	293	290	286	280	252	276	299	329	336	342	349	350	351	353	354	0	0	0
Impairment of intangible assets
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reserve for obsolete inventory
0	-	-	-	-	279	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reserve and write-off for obsolete inventory
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reserve for obsolete inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest and dividends on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11	18	0	0	0	-	-	-	-
Reserve for doubtful trade receivables
-	5	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Allowance for doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain from other non-operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	6	6	14	4	0	0	0	-	-	-	-
Amortization of deferred compensation
-	-	-	-	-	3	8	8	19	21	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation to employees - options
-	-	-	-	-	6	9	12	14	17	19	38	33	27	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Share based compensation to an employee - common stock
-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share based compensation to directors - restricted stock units
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of restricted common stock issued for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain from demutualization of insurer
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91	0	0	0
Share based compensation - shares issued to vendors
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued for the purchase of license
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share based compensation to an employees - restricted stock
-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share based compensation to non-employees - options
-	-	-	-	-	-	-	-	-	-	-	-	-	23	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Share based compensation to non-employees - restricted stock
-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in assets and liabilities
Increase in trade receivables
-1	-128	12	-81	68	-631	-373	-46	277	781	432	430	-77	138	-192	-1,181	-321	-513	896	1,720	1,859	1,899	1,003	881	41	17	0	0	0
Decrease in trade receivables - related party
-	-	-	-	-	-	-	-	-	-	-31	-31	-7	0	0	0	0	-	-	-	-	-	434	434	557	1,199	0	0	0
Decrease in notes receivables - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-176	90	134	222	266	0	0	0	-	-	-	-
Decrease in deposits and other receivables
0	-9	-60	-60	-62	-7	38	47	49	-7	-7	-51	-36	-71	-71	30	23	54	41	16	-8	37	33	-9	8	-0	0	0	0
Increase in deposit and other receivables - related party
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in license fees receivable - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-450	0	0	0
(Increase)/Decrease in inventories
-32	-14	-209	-223	-118	-83	-151	-234	-169	-119	237	315	207	187	237	395	242	226	167	66	301	-123	-300	-115	-248	37	0	0	0
Decrease in prepaid expenses
32	-103	-139	-601	-33	225	292	418	22	-123	5	5	-39	-17	-75	-34	8	76	0	0	0	-	-	-	-	-	-	-	-
Decrease in prepaid expenses - related party
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in prepaid expenses - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56	-47	72	-7	95	0	0	0
Increase in trade and other payables
-46	-443	-928	-234	701	188	429	116	-117	87	387	-64	-279	-205	-6	400	614	827	1,287	1,224	1,016	538	-195	-343	-346	116	0	0	0
Increase in operating lease liability
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase/(decrease) in trade and other payables - related party
-	-	-	-	-	-	-	-	-	-	-39	33	95	234	0	0	0	-	-	-	-	-6	-49	-0	-26	-51	0	0	0
Decrease in legal settlement liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-106	0	0	0
Increase in deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-305	-388	-472	-333	-333	-333	-333	-333	-333	0	0	0
Net cash used by operating activities
-4,292	-3,074	-5,211	-6,294	-7,450	-8,502	-7,288	-6,305	-5,319	-5,080	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,610	-5,132	-5,127	-5,052	-4,293	-3,883	-3,618	-3,500	-3,142	-2,730	0	0	0
Cash flows from investing activities:
Purchases of property, plant and equipment
-	-	-	-	-	68	85	55	75	54	72	79	56	123	140	149	152	112	60	67	69	24	48	53	115	123	0	0	0
Purchases of marketable securities
6,716	6,704	1,370	1,398	2,662	6,604	10,321	10,272	10,479	7,709	2,707	2,713	1,218	35	45	54	53	60	66	71	69	12,551	12,537	12,513	12,508	0	0	0	0
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	64	64	64	64	0	0	0	0	-	-	-	-
Proceeds from other non-operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	0	0	0	-	-	-	-	-	-	-	-
Proceeds from demutualization of insurance carrier
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	4	4	4	91	0	0	0
Proceeds from other non-operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Proceeds from sale of marketable securities
4,309	2,857	3,409	5,361	6,863	6,313	5,460	3,310	1,956	2,749	3,299	3,246	3,496	4,003	4,654	4,906	5,658	5,310	5,062	5,109	4,537	3,284	0	0	0	-	-	-	-
Net cash provided by investing activities
-2,501	-3,940	1,938	3,932	4,170	-359	-4,946	-7,017	-8,599	-5,014	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided/(consumed) by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,454	5,078	4,877	4,911	4,339	-9,286	-10,250	-11,481	-12,519	68	0	0	0
Cash flows from financing activities
Proceeds from note receivable - related party for Series A Convertible Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	225	0	0	0
Payment of short-term note payable - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	307	0	0	0	-307	0	0	0
Proceeds from other receivable for London Private Placement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Net proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	5,803	3,413	3,413	3,452	0	0	0	0	-	-	-	-	745	0	0	0	-	-	-	-
Net proceeds from the exercise of prepaid equity forward contracts for the purchase of common stock
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from exercise of warrants for common stock
-	-	-	-	-	7,155	7,835	7,835	6,454	981	301	301	244	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
0	-	-	-	-	9,105	13,901	13,901	12,480	10,460	3,714	3,714	3,697	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and restricted cash
172	-49	-1,323	-412	108	243	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of common stock in initial public offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,101	13,101	13,101	13,101	0	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,523	13,830	13,830	15,446	2,132	0	0	0
Net increase/(decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	1,904	-329	-197	118	-155	-53	-249	-141	30	352	-38	-1,151	-215	-529	0	0	0
Supplemental cash flow information:
Supplemental Schedule of Non-Cash Financing and Investing Activities
Net unrealized gains/(losses) on marketable securities
-226	43	25	33	20	-25	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right-of-use asset obtained in exchange for lease obligation
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of Series B Preferred Stock to common shares
-	-	-	-	-	1,755	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of a restricted common stock grant for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Net unrealized gains on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	6	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net unrealized gains on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13	20	6	17	-20	-11	-3	-10	0	0	0	0
Issuance of restricted common share grants to directors and officers accrued in 2014
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	697	697	697	697	0	0	0	0	-	-	-	-